Evidence map›Paper›PMID 39386586›Full record

ArticlebioRxiv : the preprint server for biology2024

MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression.

Juliana Hofstätter Azambuja, Saigopalakrishna S Yerneni, Lisa M Maurer, Hannah E Crentsil, Gabriela N Debom, Linda Klei, Mei Smyers, Chaim T Sneiderman, Kristina E Schwab, Rajesh Acharya and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Juliana Hofstätter AzambujaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-2416-7724
Saigopalakrishna S YerneniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Lisa M MaurerDepartment of Pediatrics, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
Hannah E CrentsilDepartment of Pediatrics, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
Gabriela N DebomDepartment of Neurological Surgery, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
Linda KleiDepartment of Pediatrics, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
Mei SmyersDepartment of Pediatrics, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
Chaim T SneidermanDepartment of Neurological Surgery, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
Kristina E SchwabRangos Research Center Animal Imaging Core, UPMC Children's Hospital of Pittsburgh; Pittsburgh, Pennsylvania.
Rajesh AcharyaUPMC Hillman Cancer Center; Pittsburgh, Pennsylvania.
Yijen Lin WuRangos Research Center Animal Imaging Core, UPMC Children's Hospital of Pittsburgh; Pittsburgh, Pennsylvania.
Prasanna EkambaramDepartment of Pediatrics, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.
Dong HuDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Pete J GoughPattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline; King of Prussia, Pennsylvania.
John BertinPattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline; King of Prussia, Pennsylvania.
Ari MelnickDivision of Hematology and Oncology, Cornell University, New York, New York.
Gary KohanbashDepartment of Neurological Surgery, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.ORCID 0000-0002-3953-8022
Riyue BaoUPMC Hillman Cancer Center; Pittsburgh, Pennsylvania.
Peter C LucasDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Linda M McAllister-LucasDepartment of Pediatrics, University of Pittsburgh School of Medicine; Pittsburgh, Pennsylvania.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Leonard J. Appleman · 1988 to 2026
$158.0M
Molecular Basis of Pediatric DiseaseK12HD052892 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TERENCE S. DERMODY · 2007 to 2026
$6.5M
Harnessing Tumor Associated Macrophages in GlioblastomaK99NS135130 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOFSTATTER AZAMBUJA, JULIANA · 2024 to 2025
$242k
MALT1 protease as a regulator of anti-tumor immunity and tumor progression in diffuse midline gliomaF30CA284607 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CRENTSIL, HANNAH · 2023 to 2025
$161k
NCI NIH HHS F30 CA284607NCI NIH HHS P30 CA047904NICHD NIH HHS K12 HD052892NINDS NIH HHS K99 NS135130
6 · The paper itself

Abstract

MALT1 protease is an intracellular signaling molecule that promotes tumor progression via cancer cell-intrinsic and cancer cell-extrinsic mechanisms. MALT1 has been mostly studied in lymphocytes, and little is known about its role in tumor-associated macrophages. Here, we show that MALT1 plays a key role in glioblastoma (GBM)-associated macrophages. Mechanistically, GBM tumor cells induce a MALT1-NF-κB signaling axis within macrophages, leading to macrophage migration and polarization toward an immunosuppressive phenotype. Inactivation of MALT1 protease promotes transcriptional reprogramming that reduces migration and restores a macrophage "M1-like" phenotype. Preclinical

Indexed as

brain tumorglioblastomamacrophageMALT1tumor immune microenvironment

Identifiers

PMID39386586
PMCPMC11463364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.